Welcome to our dedicated page for SS Innovations SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating regulatory nuggets about the SSi Mantra surgical robotic system inside a 300-page filing is tedious. SS Innovations’ disclosures span R&D spending for new cardiac instruments, global regulatory milestones, and surgeon adoption metrics—layers of detail that can slow decision-making.
Stock Titan solves that problem. Our AI reads every SS Innovations quarterly earnings report 10-Q filing, flags changes in production costs, and translates medical-device jargon into plain language. Wondering about SS Innovations insider trading Form 4 transactions? Receive real-time alerts the moment executives trade shares, complete with context you can understand in seconds. From the latest SS Innovations annual report 10-K simplified to a sudden SS Innovations 8-K material events explained, every document arrives on your screen as soon as it hits EDGAR—already summarized.
Use cases investors rely on daily:
- Compare R&D outlays across robotic platforms with our AI-driven 10-K analysis
- Track SS Innovations executive stock transactions Form 4 before product-launch announcements
- Review surgeon-training commitments buried in the proxy—SS Innovations proxy statement executive compensation details included
Whether you need SS Innovations SEC filings explained simply or deep SS Innovations earnings report filing analysis, our platform delivers comprehensive coverage—10-Ks, 10-Qs, 8-Ks, S-1s, and more—paired with clear, AI-powered insights so you can act with confidence.
SS Innovations International, Inc. (SSII) – Form 4 insider filing
Director and Chief Operating Officer-Americas Barry F. Cohen reported a code “G” transaction (bona-fide gift) involving the company’s common stock. On 22 May 2025, Cohen gifted 1,000,000 shares at a stated price of $0.00. Following the transaction he still beneficially owns 7,866,888 shares, held directly. No derivative securities were involved.
Because the shares were transferred without consideration, the filing does not indicate an economic sale; however, it reduces Cohen’s direct ownership by roughly 11 percent. The executive remains both a director and an officer, so his sizable post-gift stake continues to align management incentives with shareholders, but investors may wish to note the incremental decline in insider ownership.
SS Innovations International, Inc. (SSII) filed an amended Form 4 for Director and COO-Americas Barry F. Cohen. The amendment corrects the total share count after three small open-market purchases:
- 100 shares at $8.75 on 04/17/2025
- 100 shares at $8.90 on 04/22/2025
- 226 shares at $9.00 on 04/22/2025
The transactions add 426 shares in total, bringing Cohen’s directly held position to 8,866,888 common shares. No derivative securities were involved. The filing states the prior Form 4 contained an inadvertent misstatement of holdings, which is now rectified. While the dollar value of the purchases is modest, insider buying—especially by a director/officer—can be interpreted as a signal of confidence. However, the tiny size relative to Cohen’s existing 8.87 million-share stake limits financial materiality.
FAQ
What is the current stock price of SS Innovations (SSII)?
What is the market cap of SS Innovations (SSII)?
What does SS Innovations International, Inc. specialize in?
How does the company generate its revenue?
What makes the SSi Mantra surgical robotic system unique?
How is SS Innovations positioned in the competitive landscape of surgical robotics?
Which markets does SS Innovations primarily serve?
How does the company ensure compliance and quality in its operations?
